CL2023001129A1 - Terapia combinada con anticuerpos contra claudin 18.2 e inhibidores punto de control para tratar cáncer - Google Patents

Terapia combinada con anticuerpos contra claudin 18.2 e inhibidores punto de control para tratar cáncer

Info

Publication number
CL2023001129A1
CL2023001129A1 CL2023001129A CL2023001129A CL2023001129A1 CL 2023001129 A1 CL2023001129 A1 CL 2023001129A1 CL 2023001129 A CL2023001129 A CL 2023001129A CL 2023001129 A CL2023001129 A CL 2023001129A CL 2023001129 A1 CL2023001129 A1 CL 2023001129A1
Authority
CL
Chile
Prior art keywords
cancer
antibodies against
treat cancer
checkpoint inhibitors
combined therapy
Prior art date
Application number
CL2023001129A
Other languages
English (en)
Inventor
Yamada Tomohiro
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of CL2023001129A1 publication Critical patent/CL2023001129A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona una terapia de combinación para tratar y/o prevenir eficazmente enfermedades asociadas con células que expresan CLDN18.2, incluidas enfermedades cancerosas tales como cáncer gástrico, cáncer de esófago, cáncer de páncreas, cáncer de pulmón, cáncer de ovario, cáncer de colon, cáncer hepático, cáncer de cabeza-cuello y cáncer de vesícula biliar y metástasis de los mismos.
CL2023001129A 2019-08-06 2023-04-19 Terapia combinada con anticuerpos contra claudin 18.2 e inhibidores punto de control para tratar cáncer CL2023001129A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2019/056680 WO2021024020A1 (en) 2019-08-06 2019-08-06 Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer

Publications (1)

Publication Number Publication Date
CL2023001129A1 true CL2023001129A1 (es) 2023-11-24

Family

ID=68104685

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022000277A CL2022000277A1 (es) 2019-08-06 2022-02-03 Terapia combinada con anticuerpos contra claudin 18.2 e inhibidores del punto de control inmune para el tratamiento del cáncer
CL2023001129A CL2023001129A1 (es) 2019-08-06 2023-04-19 Terapia combinada con anticuerpos contra claudin 18.2 e inhibidores punto de control para tratar cáncer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2022000277A CL2022000277A1 (es) 2019-08-06 2022-02-03 Terapia combinada con anticuerpos contra claudin 18.2 e inhibidores del punto de control inmune para el tratamiento del cáncer

Country Status (16)

Country Link
US (1) US20220324965A1 (es)
EP (1) EP4010375A1 (es)
JP (1) JP2022543710A (es)
KR (1) KR20220041848A (es)
CN (1) CN114269378A (es)
AU (1) AU2020325981A1 (es)
BR (1) BR112022002196A2 (es)
CA (1) CA3149801A1 (es)
CL (2) CL2022000277A1 (es)
CR (1) CR20220051A (es)
DO (1) DOP2022000016A (es)
IL (1) IL290123A (es)
JO (1) JOP20220013A1 (es)
MX (1) MX2022000710A (es)
SG (1) SG11202113365SA (es)
WO (2) WO2021024020A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304506A (zh) * 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
WO2023013700A1 (ja) * 2021-08-04 2023-02-09 学校法人東海大学 Ｔ細胞及び／又はｂ細胞の活性調節剤を含む併用剤
TW202333785A (zh) * 2021-11-16 2023-09-01 中國大陸商蘇州創勝醫藥集團有限公司 Ｃｌａｕｄｉｎ１８．２拮抗劑和ｐｄ－１／ｐｄ－ｌ１軸抑制劑的組合療法
KR20240149438A (ko) 2022-02-27 2024-10-14 베링거 인겔하임 인터내셔날 게엠베하 Cd277 및 종양-항원에 대한 이중특이적 항체
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
WO2024126457A1 (en) * 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
DK0533838T3 (da) 1990-06-11 1998-02-23 Nexstar Pharmaceuticals Inc Nukleinsyreligander
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2340745T3 (es) 1998-12-23 2010-06-08 Pfizer Inc. Anticuerpos monoclonales humanos contra ctla-4.
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
AU7072700A (en) 1999-08-23 2001-03-19 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US6936704B1 (en) 1999-08-23 2005-08-30 Dana-Farber Cancer Institute, Inc. Nucleic acids encoding costimulatory molecule B7-4
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
PT1223980E (pt) 1999-10-28 2003-10-31 Reinhold Hofbauer Utilizacao de inibidores de csf-1
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US7034121B2 (en) 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
PL224001B1 (pl) 2002-05-02 2016-11-30 Wyeth Corp Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
KR20050059332A (ko) 2002-11-07 2005-06-17 이뮤노젠 아이엔씨 항-씨디33 항체와 이를 이용한 급성 골수성 백혈병의치료방법
EP2289936B1 (en) 2002-12-16 2017-05-31 Genentech, Inc. Immunoglobulin variants and uses thereof
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
KR101375153B1 (ko) 2003-07-02 2014-03-18 위니베르시따 디 제노바 Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및치료에서의 그 사용 방법
KR20060038461A (ko) 2003-07-24 2006-05-03 이나뜨 파르마 Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을높이는 방법 및 조성물
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
JP5295568B2 (ja) 2005-01-06 2013-09-18 ノヴォ ノルディスク アー／エス Ｋｉｒ結合剤およびその使用方法
JP5855326B2 (ja) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ES2546333T3 (es) 2005-07-01 2015-09-22 E. R. Squibb & Sons, L.L.C. Anticuerpos monoclonales humanos para ligandos 1 (PD-L1) de muerte programada
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
GB0521991D0 (en) 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
EP2604278B1 (en) 2007-01-11 2017-04-12 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
BRPI0812913B8 (pt) 2007-06-18 2021-05-25 Merck Sharp & Dohme anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CA2712220A1 (en) 2008-01-24 2009-07-30 Novo Nordisk A/S Humanized anti-human nkg2a monoclonal antibody
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
BRPI0822826A2 (pt) 2008-06-25 2015-07-07 Braasch Biotech Llc Proteína de fusão de somatostatina deficiente em cloranfenicol acetil trasferase (cat) e seus usos
DE102008036127A1 (de) 2008-08-01 2010-02-04 Emitec Gesellschaft Für Emissionstechnologie Mbh Verfahren zum Betrieb einer Abgasanlage mit Lambda-Regelung
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
KR102197527B1 (ko) 2008-09-26 2020-12-31 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
KR20190069615A (ko) 2008-12-09 2019-06-19 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010106051A1 (en) 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
CN102762593B (zh) 2009-07-31 2015-05-20 梅达雷克斯有限责任公司 抗btla的完全人抗体
WO2011026132A2 (en) 2009-08-31 2011-03-03 1/3Acamplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
MY159679A (en) 2009-12-10 2017-01-13 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
NZ626610A (en) 2010-05-04 2015-11-27 Five Prime Therapeutics Inc Antibodies that bind csf1r
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EA035033B1 (ru) 2010-11-22 2020-04-20 Иннейт Фарма Са Способ лечения гематологического предракового или гематологического ракового заболеваний
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
MX347514B (es) 2011-05-25 2017-04-28 Innate Pharma Sa Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios.
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EP2773651B1 (en) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
JP6138813B2 (ja) 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体及びその使用
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
KR20140107413A (ko) 2011-12-16 2014-09-04 화이자 인코포레이티드 암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합
WO2013119716A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
MX368507B (es) 2012-05-15 2019-10-07 Bristol Myers Squibb Co Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
SG11201407859YA (en) 2012-05-31 2014-12-30 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
WO2013181634A2 (en) 2012-05-31 2013-12-05 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP2904011B1 (en) 2012-10-02 2017-08-23 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
CN110066341B (zh) 2012-12-17 2023-01-31 Pf阿根图姆知识产权控股有限责任公司 蛋白、缀合物、药物组合物、DNA构建体、宿主细胞及制备人SIRPα融合蛋白的方法
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2016510977A (ja) 2013-02-28 2016-04-14 ユニバーシティ コート オブ ザ ユニバーシティ オブ エディンバラＵｎｉｖｅｒｓｉｔｙ Ｃｏｕｒｔ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｅｄｉｎｂｕｒｇｈ Ｃｓｆ１治療剤
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
PL2970473T3 (pl) 2013-03-14 2018-01-31 Bristol Myers Squibb Co Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
SG11201506807RA (en) 2013-03-15 2015-09-29 Glaxosmithkline Ip Dev Ltd Anti-lag-3 binding proteins
CA2910278C (en) 2013-05-02 2021-09-28 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
CN105683217B (zh) 2013-05-31 2019-12-10 索伦托治疗有限公司 与pd-1结合的抗原结合蛋白
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
WO2014207748A1 (en) 2013-06-27 2014-12-31 Alexander Biro Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
MY183503A (en) 2013-07-16 2021-02-23 Genentech Inc Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
MX2016001356A (es) 2013-08-01 2016-10-26 Ludwig Inst For Cancer Res Ltd Proteina anti-garp y sus usos.
CA3080200A1 (en) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
BR122023024195A2 (pt) 2013-09-20 2023-12-26 Bristol-Myers Squibb Company Usos de anticorpos anti-lag-3 e anticorpos anti-pd-1
EP3060581A4 (en) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
US9126984B2 (en) 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
US20160263087A1 (en) 2013-11-08 2016-09-15 Iteos Therapeutics Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
WO2015075725A1 (en) 2013-11-25 2015-05-28 Ccam Biotherapeutics Ltd. Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
EP3082802B1 (en) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
US10344090B2 (en) 2013-12-12 2019-07-09 Shanghai Hangrui Pharmaceutical Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
RS62989B9 (sr) 2014-01-15 2022-07-29 Kadmon Corporation Llc Imunomodulatorni agensi
US10711272B2 (en) 2014-01-21 2020-07-14 City Of Hope CTLA-4 aptamer siRNA species
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX2016009010A (es) 2014-01-28 2017-01-18 Bristol Myers Squibb Co Anticuerpos anti-gen de activacion de linfocitos (lag-3) para tratar neoplasias hematologicas.
US9758505B2 (en) 2014-02-12 2017-09-12 Iteos Therapeutics 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
JP2017507983A (ja) 2014-03-18 2017-03-23 アイティーオス セラペウティクス 新規な３−インドール置換誘導体、医薬組成物、および使用方法
PT3125883T (pt) 2014-04-04 2020-10-12 Iomet Pharma Ltd Derivados de indol para utilização na medicina
WO2015174439A1 (ja) 2014-05-13 2015-11-19 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
KR20210149870A (ko) 2014-05-13 2021-12-09 메디뮨 리미티드 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
US9603836B2 (en) 2014-05-15 2017-03-28 Iteos Therapeutics Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
ES2753360T3 (es) 2014-05-29 2020-04-08 Spring Bioscience Corp Anticuerpos contra PD-L1 y usos de los mismos
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
TWI687438B (zh) 2014-07-03 2020-03-11 英屬開曼群島商百濟神州生物科技有限公司 抗ｐｄ-ｌ１抗體及其作為治療及診斷之用途
SG11201700207WA (en) 2014-07-11 2017-02-27 Genentech Inc Anti-pd-l1 antibodies and diagnostic uses thereof
US10435470B2 (en) 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
GB201414730D0 (en) 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
RU2017105425A (ru) 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
MX2017002856A (es) 2014-09-10 2017-05-30 Innate Pharma Anticuerpos siglec de reaccion cruzada.
DK3193929T3 (da) 2014-09-16 2019-08-19 Innate Pharma Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
US10590086B2 (en) 2014-11-03 2020-03-17 Iomet Pharma Ltd. Pharmaceutical compound
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
CA2967118A1 (en) 2014-11-10 2016-05-19 Medimmune Limited Binding molecules specific for cd73 and uses thereof
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
EP3253796A1 (en) 2015-02-03 2017-12-13 Université Catholique de Louvain Anti-garp protein and uses thereof
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
PT3295951T (pt) 2015-02-19 2020-07-21 Compugen Ltd Anticorpos anti-pvrig e métodos de utilização
WO2016134335A2 (en) 2015-02-19 2016-08-25 Compugen Ltd. Pvrig polypeptides and methods of treatment
US10336824B2 (en) 2015-03-13 2019-07-02 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
JP6775516B2 (ja) 2015-03-17 2020-10-28 ファイザー・インク 新奇な３−インドール置換誘導体、医薬組成物、および使用方法
US10836827B2 (en) 2015-03-30 2020-11-17 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
WO2016181349A1 (en) 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
EP3325009A4 (en) 2015-07-22 2018-12-05 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
CN108976300B (zh) 2015-07-30 2023-04-14 宏观基因有限公司 Pd-1结合分子和其使用方法
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP3331901A1 (en) 2015-08-07 2018-06-13 Pieris Pharmaceuticals GmbH Novel fusion polypeptide specific for lag-3 and pd-1
WO2017025868A1 (en) 2015-08-10 2017-02-16 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
SG10201913276WA (en) 2015-09-01 2020-02-27 Agenus Inc Anti-pd-1 antibodies and methods of use thereof
RU2022108079A (ru) 2015-09-24 2022-04-08 Дайити Санкио Компани, Лимитед Антитело против garp
PL3356413T3 (pl) 2015-10-01 2022-04-19 Potenza Therapeutics, Inc. Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
EP3368575A2 (en) 2015-10-29 2018-09-05 Alector LLC Anti-siglec-9 antibodies and methods of use thereof
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
EP3377533A2 (en) 2015-11-19 2018-09-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
KR20180086502A (ko) 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항원-결합 단편
US20190023786A1 (en) 2016-01-12 2019-01-24 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
US9624185B1 (en) 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017132825A1 (zh) 2016-02-02 2017-08-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
CN109195990A (zh) 2016-03-30 2019-01-11 Musc研究发展基金会 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
PL3458478T3 (pl) 2016-05-18 2021-06-28 Boehringer Ingelheim International Gmbh Przeciwciała anty pd-1 i anty-lag3 do leczenia nowotworu
SG11201810612TA (en) 2016-05-30 2018-12-28 Astellas Pharma Inc Novel genetically engineered vaccinia viruses
ES2858091T3 (es) 2016-06-20 2021-09-29 F Star Therapeutics Ltd Moléculas de unión que se unen a PD-L1 y LAG-3
TW201831513A (zh) 2016-06-20 2018-09-01 Ｆ星貝塔有限公司 結合物件(一)
CN108472349B (zh) 2016-06-23 2022-05-24 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
WO2018017864A2 (en) 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
WO2018022831A1 (en) 2016-07-28 2018-02-01 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
MX2019001471A (es) 2016-08-05 2019-10-30 Allakos Inc Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EP3496751B1 (en) 2016-08-08 2022-10-19 Acetylon Pharmaceuticals Inc. Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof
AU2017313496B2 (en) 2016-08-15 2023-09-21 Fuso Pharmaceutical Industries, Ltd. Anti-LAG-3 antibody
AU2017313405B2 (en) 2016-08-17 2024-09-26 Compugen Ltd. Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
WO2018069500A2 (en) 2016-10-13 2018-04-19 Symphogen A/S Anti-lag-3 antibodies and compositions
EP3689419A1 (en) 2016-11-01 2020-08-05 AnaptysBio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
WO2018106529A1 (en) 2016-12-08 2018-06-14 Eli Lilly And Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
CN107058315B (zh) 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
CN110072891A (zh) 2016-12-13 2019-07-30 安斯泰来制药株式会社 抗人cd73抗体
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
JP2020522495A (ja) 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
WO2019000146A1 (zh) 2017-06-26 2019-01-03 深圳市博奥康生物科技有限公司 一种人程序性死亡受体1基因的siRNA及其应用
US11623954B2 (en) 2017-07-10 2023-04-11 Innate Pharma Siglec-9-neutralizing antibodies
CA3066571A1 (en) 2017-07-10 2019-01-17 Innate Pharma Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
CN111867630B (zh) * 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
PE20211400A1 (es) * 2018-08-03 2021-07-27 Amgen Res Munich Gmbh Constructos de anticuerpos para cldn18.2 y cd3
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途

Also Published As

Publication number Publication date
CL2022000277A1 (es) 2022-11-11
CR20220051A (es) 2022-03-24
BR112022002196A2 (pt) 2022-05-03
CA3149801A1 (en) 2021-02-11
US20220324965A1 (en) 2022-10-13
MX2022000710A (es) 2022-02-23
AU2020325981A1 (en) 2022-03-03
DOP2022000016A (es) 2022-06-30
WO2021025177A1 (en) 2021-02-11
KR20220041848A (ko) 2022-04-01
EP4010375A1 (en) 2022-06-15
JOP20220013A1 (ar) 2023-01-30
SG11202113365SA (en) 2021-12-30
CN114269378A (zh) 2022-04-01
IL290123A (en) 2022-03-01
WO2021024020A1 (en) 2021-02-11
JP2022543710A (ja) 2022-10-13

Similar Documents

Publication Publication Date Title
CL2023001129A1 (es) Terapia combinada con anticuerpos contra claudin 18.2 e inhibidores punto de control para tratar cáncer
EP4331578A3 (en) Drug conjugates comprising antibodies against claudin 18.2
BR112014028948B8 (pt) combinação de terapia envolvendo anticorpos contra claudin 18.2 para o tratamento de câncer
MX2020011796A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2018008514A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
EA201991622A1 (ru) Комплексная терапия для лечения рака
EP4364756A3 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2020115491A3 (en) Immune checkpoint inhibitor in combination with sonodynamic therapy
EA202191086A1 (ru) Комбинированная терапия меланомы
EP3758735A4 (en) BIFUNCTIONAL PROTEINS IN COMBINATION WITH CHECKPOINT BLOCKADE FOR TARGETED THERAPY
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
CL2023002818A1 (es) Terapia de combinación que implica anticuerpos contra claudina 18.2 para el tratamiento del cáncer
EA201990370A1 (ru) Терапия рака, связанная с crebbp
MX2019004410A (es) Particulas citotoxicas.
MX2020007665A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020007681A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020007664A (es) Terapia de combinacion para tratar o prevenir el cancer.
EA202190600A1 (ru) Комбинированная терапия для лечения рака предстательной железы